28547-15-1

Usage

Uses

Used in Pharmaceutical Industry:
3-Benzenesulfonylaminobenzoic acid is used as an inhibitor of glycerol 3-phosphate acyltransferase (GPAT) for the development of novel therapeutic agents. GPAT is an enzyme involved in the synthesis of glycerolipids, which are essential components of cell membranes and energy storage molecules. Inhibiting GPAT can have potential applications in the treatment of various diseases, such as obesity and type 2 diabetes, by modulating lipid metabolism.
Used in Research and Development:
3-Benzenesulfonylaminobenzoic acid can be utilized as a chemical probe in the study of GPAT enzyme function and its role in lipid metabolism. 3-BENZENESULFONYLAMINOBENZOIC ACID can help researchers understand the molecular mechanisms underlying GPAT inhibition and its potential therapeutic implications.
Used in Drug Design and Synthesis:
The unique chemical structure of 3-benzenesulfonylaminobenzoic acid makes it a valuable starting material for the design and synthesis of new drugs targeting GPAT and other related enzymes. By modifying its structure, chemists can potentially develop more potent and selective inhibitors with improved pharmacological properties.

InChI:InChI=1/C13H11NO4S/c15-13(16)10-5-4-6-11(9-10)14-19(17,18)12-7-2-1-3-8-12/h1-9,14H,(H,15,16)

Upstream product

• 99-05-8 meta-aminobenzoic acid 
• 98-09-9 benzenesulfonyl chloride 
• 4518-10-9 Methyl 3-aminobenzoate 
• 107922-46-3 methyl 3-(phenylsulfonamido)benzoate 
• 121-92-6 3-nitrobenzoic acid 
• 98-80-6 phenylboronic acid 

Downstream Products

• 1253738-63-4 N-[5-[acetyl(methyl)amino]-1-(1-methylethyl)-1H-benzimidazol-2-yl]-3-[(phenylsulfonyl)amino]benzamide 
• 1253738-67-8 N-{5-[acetyl(methyl)amino]-1-butyl-1H-benzimidazol-2-yl}-3-[(phenylsulfonyl)amino]benzamide 
• 1253738-69-0 N-{5-[acetyl(methyl)amino]-1-phenyl-1H-benzimidazol-2-yl}-3-[(phenylsulfonyl)amino]benzamide 
• 1253738-75-8 ethyl 3-{5-[acetyl(methyl)amino]-2-[({3-[(phenylsulfonyl)amino]phenyl}carbonyl)amino]-1H-benzimidazol-1-yl}propanoate 
• 1253738-88-3 1,1-dimethylethyl 2-[({3-[(phenylsulfonyl)amino]phenyl}carbonyl)amino]-1-propyl-1H-benzimidazole-5-carboxylate 
• 1253736-90-1 N-[1-(3-hydroxypropyl)-1H-benzimidazol-2-yl]-3-[(phenylsulfonyl)amino]benzamide 
• 1253736-97-8 1,1-dimethylethyl {2-[({3-[(phenylsulfonyl)amino]phenyl}carbonyl)amino]-1-propyl-1H-benzimidazol-5-yl}carbamate 
• 1253737-02-8 1,1-dimethylethyl methyl{2-[({3-[(phenylsulfonyl)amino]phenyl}carbonyl)amino]-1-propyl-1H-benzimidazol-5-yl}carbamate 

Relevant academic research and scientific papers

Hydroxamic acid with benzenesulfonamide: An effective scaffold for the development of broad-spectrum metallo-β-lactamase inhibitors

Given that β-lactam antibiotic resistance mediated by metallo-β-lactamases (MβLs) seriously threatens human health, we designed and synthesized nineteen hydroxamic acids with benzenesulfonamide, which exhibited broad-spectrum inhibition against four teste

Sequential C-S and S-N Coupling Approach to Sulfonamides

A one-pot three-component reaction involving nitroarenes, (hetero)arylboronic acids, and potassium pyrosulfite leading to sulfonamides was described. A broad range of sulfonamides bearing different reactive functional groups were obtained in good to excellent yields through sequential C-S and S-N coupling that does not require metal catalysts.

Design, synthesis and biological activity of N-(3-substituted-phenyl)benzenesulfonamides as selective and reversible LSD1 inhibitors

Lysine specific demethylase 1?plays a crucial role in regulating histone methylation at residues K4 and K9 on histone H3 and over-expresses in a variety of cancers. Here we designed, synthesized and evaluated a series of N-(3-substituted-phenyl)benzenesul

BENZIMIDAZOLECARBOXAMIDES AS INHIBITORS OF FAK

This invention relates to benzimadolecarboxamides of formula (I) which are inhibitors of focal adhesion kinase, and as such are useful for treating proliferative diseases

NOVEL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS CONTAINING SAME, METHODS OF USE FOR SAME, AND METHODS FOR PREPARING SAME

The present invention relates to a novel class of compounds comprising formula I, wherein n is 0 or 1. A is NR1, O, or S, wherein R1 is H, hydroxyl, C1-C10 alkyl, C1-C10 alkoxy, alkenyl, aryl, alkylaryl or arylalkyl. X is a carboxylate, a phosphonate, or a phosphate residue, or a C1-C10 alkyl residue optionally substituted with a carboxylate, phosphonate or phosphate residue. Y is a C1-C20 alkyl, alkenyl, halide, hydroxyl, C1-C20 alkoxy, aryl, alkylaryl, arylalkyl, cycloalkyl, cycloalkenyl, or a heterocyclic ring and is optionally substituted with one or more halides. Z is a H, a hydroxyl group, a halide, an aryl group, an alkylaryl group, an arylalkyl group, a cycloalkyl group, a cycloalkenyl group or a heterocyclic ring and is optionally substituted with one or more C1-C10 alkyl groups, C1-C10alkoxy groups, hydroxyl groups, cyano groups, carboxylate groups, halides, aryl groups, alkylaryl groups, arylalkyl groups, cycloalkyl groups, cycloalkenyl groups or heterocyclic rings.

Design and synthesis of small molecule glycerol 3-phosphate acyltransferase inhibitors

The incidence of obesity and other diseases associated with an increased triacylglycerol mass is growing rapidly, particularly in the United States. Glycerol 3-phosphate acyltransferase (GPAT) catalyzes the ratelimiting step of glycerolipid biosynthesis, the acylation of glycerol 3-phosphate with saturated long-chain acyl-CoAs. In an effort to produce small molecule inhibitors of this enzyme, a series of benzoic and phosphonic acids was designed and synthesized. In vitro testing of this series has led to the identification of several compounds, in particular 2-(nonylsulfonamido)benzoic acid (15g), possessing moderate GPAT inhibitory activity in an intact mitochondrial assay.

NOVEL SULFONE AMIDE DERIVATIVES CAPABLE OF INHIBITING BACE

The present invention relates to novel derivatives of sulfone amide of Formula 1 as defined in this disclosure which inhibit the activity of BACE (or beta-secretase). These sulfone amide derivatives are useful for the treatment and prevention of Alzheimer's disease and related diseases caused by production of beta-amyloid, by inhibiting the activity of BACE.

Arylsulfonylaminobenzene derivatives and the use thereof as factor Xa inhibitors

The present invention is directed to non-peptidic factor Xa inhibitors which are useful for the treatment of arterial and venous thrombotic occlusive disorders, inflammation, cancer, and neurodegenerative diseases. The factor Xa inhibitors provide compounds of structure: STR1 or pharmaceutically acceptable salts thereof; wherein R1 is alkyl, substituted alkyl, cycloalkyl, aryl, substituted aryl, heteroaryl or substituted heteroaryl; R2 is one of hydrogen, alkyl, cycloalkyl or aryl; R3 is one of hydrogen, hydroxy or alkoxy; R4 is one of --NH2, phenyl or pyridyl, wherein said phenyl and said pyridyl are optionally substituted with one or two of halogen, hydroxy, hydroxyalkyl, alkoxy, amino, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl and/or dialkylaminoalkyl; X is one of --CH2 -- or --C(O)--; and n is from zero to eleven; provided that when R4 is --NH2, then R3 is hydrogen and n is other than zero; and also provided that when R3 is hydroxy or alkoxy, then R4 is other than --NH2, and n is other than zero.

Studies on Potential Antibacterial and Chelating Agents: Part III - Synthesis, Characterization and Biological Activity of Co(II), Ni(II) and Cu(II) Chelates with Some Sulphonamido and Benzamido Derivatives of Aminobenzoic Acids

The complexing behaviour of some amidobenzoic acids towards Co(II), Ni(II) and Cu(II) has been studied.Eleven complexes of the type M(RH)2 where RH2 = o, m and p-benzenesulphonamidobenzoic acids, o-(p-toluenesulphonamido)benzoic acid and o-benzamidobenzoi